Dotatate PET
Dotatate PET/CT
High-sensitivity PET imaging of somatostatin receptor-positive neuroendocrine tumors
Exam Overview
This patient has a clinical history of colonic neuroendocrine cancer and known metastases to the liver, treated with surgical resections and on maintenance therapy
Dotatate PET/CT Findings
NCPIC's Dotatate PET/CT shows numerous intrahepatic metastatic masses, some of them with necrosis, and nodal metastases above and below the diaphragm, as well as multiple sites of bone metastasis.
Ordering Guidelines - Dotatate PET/CT
- Patients with history of or newly diagnosed/biopsy proven neuroendocrine tumor (NET) or carcinoid tumor for restaging or initial staging.
- Patients with CT or MRI imaging features suspicious for NET or carcinoid tumor.
- Patients with biochemical evidence/data suspicious for NET or carcinoid tumor. The general biochemical marker is chromogranin A (CgA) in the blood, or 24-h urine 5-HIAA (5-hydroxyindoleacetic acid), or elevated hormone levels suggesting GI or pancreatic endocrine tumors or pheochromocytoma/paragangliomas, just to name a few.
Radiopharmaceutical Understanding
DOTATATE PET/CT is one of the most precise imaging tools for neuroendocrine tumors. It allows your care team to understand the extent of disease and tailor treatment accordingly.
Did You Know?
Apple co-founder Steve Jobs was diagnosed with a rare pancreatic neuroendocrine tumor (pNET)? His case helped draw public attention to neuroendocrine cancers and underscores the importance of timely, evidence-based treatment. Please speak with your care team about any questions regarding diagnosis, treatment options, or follow-up care.
Locations
Sacramento
Rocklin